Combination of RUNX1 inhibitor and gemcitabine mitigates chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress

BACKGROUND: Gemcitabine (GEM)-based chemotherapy is the first-line option for pancreatic ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its efficacy, and the specific mechanisms remain largely unknown. RUNX1, a key transcription factor in hematopoiesis, also involve...

Descripción completa

Detalles Bibliográficos
Autores principales: She, Chunhua, Wu, Chao, Guo, Weihua, Xie, Yongjie, Li, Shouyi, Liu, Weishuai, Xu, Chao, Li, Hui, Cao, Pei, Yang, Yanfang, Wang, Xiuchao, Chang, Antao, Feng, Yukuan, Hao, Jihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494371/
https://www.ncbi.nlm.nih.gov/pubmed/37697370
http://dx.doi.org/10.1186/s13046-023-02814-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494371/
https://www.ncbi.nlm.nih.gov/pubmed/37697370
http://dx.doi.org/10.1186/s13046-023-02814-x

Ejemplares similares